Home › Skin Cancer › Florida › Orlando
Skin Cancer clinical trials in Orlando, FL
4 studies for Skin Cancer are looking for participants at sites in and around Orlando (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
RecruitingPhase 1/2
- Orlando Health Cancer Institute (Melanoma/NSCLC), Orlando
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
RecruitingPhase 3
- Orlando Health Cancer Institute, Orlando
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients
Recruiting
- Day Star Skin Cancer Center, Poinciana · 28 mi away
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RecruitingPhase 1/2
- Orlando Health Cancer Institute, Orlando
About Skin Cancer
Try ABCDE on a mole to check for signs of skin cancer: Asymmetry, Border, Color, Diameter, Elevation. Learn more on advanced detection and treatments.
More about Skin Cancer on MedlinePlus
Skin Cancer trials in other cities
- Boston, MA8 studies
- Tampa, FL7 studies
- New York City, NY7 studies
- Washington, DC6 studies
- Pittsburgh, PA6 studies
- Salt Lake City, UT6 studies
- Rochester, MN5 studies
- Houston, TX5 studies
- Los Angeles, CA5 studies
- St. Louis, MO4 studies
- Atlanta, GA4 studies
- Edison, NJ4 studies
Other studies in Orlando
- Non-Small Cell Lung Cancer44 studies
- Obesity32 studies
- Metastatic Cancer29 studies
- Overweight27 studies
- Alzheimer's Disease25 studies
- Type 2 Diabetes25 studies
- Cancer (all types)24 studies
- Breast Cancer23 studies
- Ovarian Cancer22 studies
- Ulcerative Colitis22 studies
- Lung Cancer21 studies
- Colorectal Cancer19 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.